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Abstract 
Cervical cancer is a major public health concern in Morocco where it represents the second most 
common and lethal cancer in women. Human papillomavirus (HPV) vaccines have been licensed in 
Morocco since 2008 but there is no available data on their acceptability. This study aimed to assess 
awareness of HPV and the vaccine, and to identify factors associated with acceptability of the vaccine 
among parents in Morocco. A questionnaire-based survey using face-to-face interviews was conducted 
in a sample of 852 parents (670 mothers and 182 fathers) with at least one unmarried daughter ≤26 
years. The study took place within public and private health centres and clinics in four regions in 
Morocco between July and August 2012. The main outcome measure was willingness to consider 
vaccinating a daughter against HPV. Responses revealed very low awareness of HPV infection (5%) 
and the HPV vaccine (14%). None of the participants had vaccinated their daughters against HPV and 
only 35% (32% of mothers and 45% of fathers) were willing to consider doing so in the future. Higher 
education and income, previous awareness of the HPV vaccine and endorsement of the belief that a 
recommendation from the ministry of health or a doctor to have the vaccine would be encouraging, 
were associated with mothers’ HPV vaccine acceptance. Non-acceptance among mothers was 
associated with having more than two daughters, believing the vaccine was expensive and lack of 
information. The only factor associated with the fathers’ acceptance of the vaccine was the cost. 
Increasing HPV and HPV vaccine awareness through educational campaigns, along with active 
recommendation by physicians and a publically funded vaccination programme could increase 
parental acceptance of the vaccine in Morocco. 
© 2014 The Authors. Published by Elsevier B.V. 
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Introduction 
Cervical cancer is the second most common and lethal cancer in women in Morocco with a mortality 
rate of 8.4/100,000 which is the highest amongst all North African countries [1]. Thus, it is considered 
as a real public health concern. The prevention constitutes an efficient mean to reduce its incidence 
and the related mortality. Human Papilloma Viruses (HPV) are associated at 99,7% to this cancer [2]. 
Currently, two HPV vaccines had been developed and were licensed in Morocco since 2008 [3]. 
Clinical trials revealed high efficiency and efficacy of these vaccines [4]. However, many challenges 
are facing this prevention strategy, particularly its acceptability by the population. In fact, the younger 
age of the target group (girls between 9 and 26 years) and the sexual aspect of the vaccine imply a 
central role of parental acceptability in the success of any vaccination intervention. 
Interestingly many studies assessing parental HPV vaccination acceptability had been conducted in 
different populations. However no one is so far published neither within the Moroccan population nor 
any other Arab-Islamic societies, known for their sexual conservatism. The present study is aiming 
particularly to assess awareness about HPV and the vaccine, and to identify factors associated with 
acceptability of the vaccine among parents in Morocco.  
Methodology 
Face-to-face interviews were conducted with 852 parents (670 mothers and 182 fathers) having at least 
one unmarried daughter ≤26 years. A questionnaire developed and validated by multidisciplinary team 
(researchers, doctors, psychologists and epidemiologists) was used in this study (Appendix A). 
Foreign people and Moroccans living aboard were not included in the survey. The survey took place in 
hospitals, public health centers and privates clinics within four areas in Morocco. Univariate logistic 
regression and hierarchical multiple logistic regression analyses were used to investigate associations 
between: (i) demographic and cultural predictors and (ii) attitudinal predictors of parental HPV 
vaccine acceptability. The first multivariate model included demographic and cultural variables that 
had significant univariate associations with HPV vaccine acceptability (p < 0.05). The second 
multivariate model included demographic, cultural andattitudinal variables that had significant 
univariate associationswith vaccine acceptability. This enabled us to see whether attitudes were 
significantly associated with vaccine acceptability, after controlling for the demographic and cultural 
variables. Separate analyses were carried out for women and men as the predictors of vaccine 
acceptability were found to differ by gender. Analyses were performed using SPSS v.20 [5]. 
Associations were consideredstatistically significant at p< 0.05.  
Results and Discussion 
1. Awareness about cervical cancer, HPV and the vaccine  
Results have shown that the vast majority (91%) of the participants have heard about cervical cancer 
(Fig 1, a). However, only 5% stated having heard about HPV which clearly reflect a weak awareness 
of the participants about the causative link between cervical cancer and HPV infection (Fig 1, b). 
Nevertheless when asked about the vaccine, more that 14% were aware of it (Fig 1, c). This could be 
explained by the fact that the vaccine is more known as a cervical cancer than an HPV vaccine. 
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2. HPV vaccination coverage and parental acceptability level  
A striking result was that none of the parents had vaccinated their daughter(s). This could be due to the 
low public awareness, but also to the lack of a national vaccination programme. To assess the HPV 
vaccine acceptability within our study population, as the main aim of the present work, it was 
necessary to provide participants with brief information about important points related to cervical 
cancer, HPV and the vaccine. As shown the figure 2, the assessment of parental willingness to 
vaccinate their daughter(s) revealed that only 35% of parents were willing to, while the others were 









This low acceptability rate was expected since we thought that in such a very conservative society 
where sexuality is highly governed by many cultural and religious considerations the vaccination 
about a sexual transmitted infection could face some resistances. 
3. Parental  attitudes towards HPV vaccination  
In front of this low acceptability, it is interesting to evaluate parental attitudes towards this vaccine and 
identify factors that are really associated to its acceptability within the Moroccan society. Thus, on the 
basis of the literature, we identified six statements that allow an assessment of parental attitudes 
towards HPV vaccination; Participants were asked to respond if: 1) The price of the vaccine is very 
expensive, 2) They don’t have sufficient information about the vaccine, 3) whether the vaccination 
could encourage sexual liberty in their daughters, an extensively discussed point in HPV vaccination, 
4) they think that the vaccine don’t provide a full protection, 5) they have concerns about post vaccine 
complications and 6) they prefer to wait as the vaccine is so new. As shown in the figure 3 we found 
that 75% of the participants confirm that the vaccine is expensive and 97% stated don’t have sufficient 
information about. In respect to the fact that the vaccine would encourage sexual liberty, surprisingly; 
almost all respondents disagreed with this idea. We considered this as an interesting finding within 
Figure 1. Awareness of cervical cancer (a), HPV (b) and HPV/Cervical cancer Vaccine 
Figure 2. Parental Willingness to vaccinate their daughter(s) 
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such a conservative society.The vast majority of parentsexplained this attitude by the fact that 
daughters could not become sexually active before marriage and “if a girl decided to have illegal sex, 
being unvaccinated against HPV will not prevent her doing so”. For parental attitudes towards vaccine 
efficacy, we can notice that more than 36% stated “do not know” which support results about 
insufficient information.Parental responses about their concerns related to the “post vaccine 
complications” and the fact that “the vaccine it is so new and they prefer to wait” do not revealed 
particular differences between those agreeingit and those who do not agreed. 
 
 
4. Predictors of parental acceptability of the vaccine 
In this work we were interested in identifying factors associated with parental acceptability of HPV 
vaccination in Morocco. We found thatmothers’ acceptability of the vaccine was positively associated 
with education, income and awareness about the vaccine. However having more than two daughters 
and vaccine expense were negative correlates. In the regard of those results we can notice that 
mothers’ acceptability of the vaccine in Morocco seems to be related to two aspects: the awareness 
about the vaccine and its cost. For fathers, only the cost was found to be associated with their vaccine 
acceptability. Overall, these results are in line with many previously published works showing the 
positive role of parental awareness about the vaccine on its parental acceptability. Conversely, the cost 
of the vaccine was broadly described as a real barrier to HPV vaccination, especially in low and 
middle income countries [6, 7]. Exhaustive results of the analyses of HPV vaccination acceptability 
predictors in Moroccan mothers and fatherscould be found in Table 1 and 2, respectively (Appendix 
B). 
Figure 3. Parental attitudes towards HPV vaccination 
72   M. Mouallif et al. /  Procedia in Vaccinology  8 ( 2014 )  68 – 76 
5.  Parents’ most encouraging reason to vaccinate daughters 
On the basis of data available in the literature, we determined tree reasons that would encourage 
parents to vaccinate daughter(s) against the HPV: (1) if the vaccine is recommended by the ministry 
of health or a doctor, (2) if it is available for free and (3) if some family members vaccinate their 
daughter(s). Here, participants were asked which will be the most important reason that will 
encourage them to vaccinate their daughter(s). Interestingly and reassuringly almost all 
parents,including those who were unwilling to vaccinate, stated they would be encouraged to 
vaccinate their daughter(s) if the vaccine was recommended by the Ministry of Health or a doctor 
(51%) or if it was free of charge(35%) which has increased the acceptability rate to 86%. This 
further emphasises cost as a barrier to HPV vaccination and also reveals the important influence that 
a recommendation from the health care system could have on vaccine acceptability, as found in 
previous research [8, 9].However, no data are available on whether Moroccan physicians are 
supportive of HPV vaccination or not. Thus, further evaluation of Moroccan healthcare provider 
beliefs is needed. 
Conclusions 
Our results indicate worryingly a low awareness about HPV infection, and HPV vaccine among 
parents in Morocco. This situation needs to be urgently addressed given its potential negative impact 
on women’s access to cervical cancer prevention. In fact this could be clearly mirrored by the null 
vaccination rate found in our population. Educational campaigns are then needed and should aim to 
increase awareness and importance of the HPV vaccine, which may help improve parental vaccine 
acceptability. Encouraging health care providers to recommend HPV vaccination within the health 
care system could also improve vaccine acceptability. We found that parental fears that the vaccine 
might promote sexual liberty were not barriers. We found however thatthe cost of the vaccine will 
constitute a real barrier to the HPV vaccination in Morocco. Thus, if an HPV vaccination program 
were to be implemented, the cost of the vaccine would need to be low to ensure high vaccine uptake. 
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Table 1. Demographic and attitudinal predictors of mother’s HPV vaccine acceptability: univariate and multivariate analyses 
  Univariate analyses (n=669  Multivariate analyses (n=538)  
Model 1b Model 2c 
Categorical variables Total sample (n=670)a OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
Education        
None 37.9 (254) 1.00  1.00  1.00  
Primary 34.5 (231) 2.69 (1.78-4.06) <0.001 1.84 (1.14-2.97) 0.013 1.30 (0.77-2.21) 0.331 
Secondary 16.6 (111) 3.27 (2.00-5.34) <0.001 2.01 (1.10-3.69) 0.024 1.14 (0.59-2.22) 0.700 
High school/Uni 10.9 (73) 3.25 (1.85-5.70) <0.001 1.70 (0.78-3.72) 0.184 0.60 (0.25-1.46) 0.260 
Missing   0.1 (1)       
Income        
Low 56.7 (380) 1.00  1.00  1.00  
Medium 17.6 (118) 3.31 (2.14-5.10) <0.001 2.23 (1.36-3.66) 0.002 1.76 (1.03-3.00) 0.039 
High 17.8 (119) 2.88 (1.87-4.46) <0.001 2.19 (1.23-3.88) 0.008 1.21 (0.64-2.29) 0.566 
Missing   7.9 (53)       
Living area        
Urban 74.0 (496) 1.00      
Rural 26.0 (174) 0.71 (0.48-1.04) 0.076     
Number of daughters        
1 52.1 (349) 1.00  1.00  1.00  
2 26.6 (178) 0.70 (0.47-1.02) 0.065 0.72 (0.46-1.12) 0.142 0.66 (0.41-1.07) 0.095 
More than 2 21.3 (143) 0.39 (0.24-0.62) <0.001 0.53 (0.31-0.92) 0.025 0.66 (0.36-1.20) 0.170 
Experience of CaCx        
No 69.7 (467) 1.00    1.00  
Yes 23.9 (160) 1.64 (1.13-2.38) 0.009   1.41 (0.88-2.26) 0.148 
Missing   6.4 (43)       
Heard of Pap test        
No 49.1 (329) 1.00    1.00  
Yes 44.6 (299) 1.69 (1.21-2.37) 0.002   1.08 (0.69-1.68) 0.737 
Missing   6.3 (42)       
Heard of HPV        
No 95.8 (642) 1.00      
Yes   4.2 (28) 1.86 (0.87-3.97) 0.111     
Heard of HPV vaccine        
No 85.8 (575) 1.00    1.00  
Yes 14.2 (95) 2.85 (1.83-4.43) <0.001   1.93 (1.08-3.46) 0.027 
Vaccine decision maker        
Father No 91.9 (616) 1.00      
 Yes   7.9 (53) 0.89 (0.48-1.64) 0.710     
Mother No 70.9 (475) 1.00      
 Yes 29.0 (194) 0.97 (0.68-1.38) 0.853     
Both No 43.1 (289) 1.00      
 Yes 56.7 (380) 1.03 (0.74-1.42) 0.883     
Doctor No 95.8 (642) 1.00    1.00  
 Yes   4.0 (27) 2.32 (1.07-5.03) 0.033   1.60 (0.60-4.26) 0.348 
Herself No 88.7 (594) 1.00      
 Yes   11.2 (75) 1.36 (0.83-2.23) 0.226     
Strongest reason to 
encourage acceptance 
       
Recommended by Ministry 
of Health/Doctor 
46.6 (312) 1.00    1.00  
Vaccine free 39.1 (262) 0.19 (0.13-0.28) <0.001   0.28 (0.17-0.48) <0.001 
Family member vaccinated 
their daughter 
  5.5 (37) 0.59 (0.33-1.05) 0.073   0.97 (0.49-1.91) 0.918 
Missing   0.3 (2)       
Continuous variables Range Mean (SD)       
Age 19-67 37.25 (9.59) 0.98 (0.96-1.00) 0.028 0.99 (0.97-1.02) 0.559 0.99 (0.97-1.02) 0.469 
Whatever happens to my 
health is God’s will 
  1-5   4.89 (0.37) 0.41 (0.25-0.67) <0.001   0.32 (0.16-0.62) 0.001 
Vaccine is expensive   1-5   4.14 (1.29) 0.67 (0.59-0.76) <0.001   0.83 (0.70-0.97) 0.023 
Insufficient information   1-5   4.70 (0.59) 0.65 (0.49-0.84) 0.001   0.58 (0.41-0.83) 0.003 
Encourages sexual liberty   1-5   2.10 (1.22) 0.95 (0.83-1.10) 0.491     
Vaccine doesn’t fully 
protect 
  1-5   2.84 (1.12) 1.02 (0.85-1.22) 0.832     
Concerns about post-
vaccine complications 
  1-5   3.28 (1.41) 0.93 (0.83-1.05) 0.230     
Vaccine is new, want to wait   1-5   3.26 (1.47) 0.92 (0.83-1.03) 0.157     
an varies between items because of missing data 
bModel 1 predicts 9.7-13.4% of the variance in vaccine acceptability (Cox and Snell R2=0.097, Nagelkerke R2=0.134) 
cModel 2 predicts 21.4-29.4% of the variance in vaccine acceptability (Cox and Snell R2=0.214, Nagelkerke R2=0.294) 
Appendix B 
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Table 2. Demographic and attitudinal predictors of father’s HPV vaccine acceptability: univariate and multivariate analyses 
  Univariate analyses (n=180)a Multivariate analyses (n=134)b 
Categorical variables Total sample (n=182)a OR (95% CI) p-value OR (95% CI) p-value 
Education      
None 14.8 (27) 1.00    
Primary 29.1 (53) 0.82 (0.31-2.18) 0.695   
Secondary 29.7 (54) 1.43 (0.55-3.72) 0.465   
High school/Uni 26.4 (48) 2.24 (0.84-5.95) 0.106   
Income      
Low 41.2 (75) 1.00    
Medium 19.8 (36) 1.24 (0.55-2.78) 0.610   
High 31.9 (58) 1.57 (0.79-3.14) 0.201   
Missing   7.1 (13)     
Living area      
Urban 73.1 (133) 1.00    
Rural 26.9 (49) 0.79 (0.41-1.54) 0.491   
Number of daughters      
1 56.0 (102) 1.00    
2 26.4 (48) 0.50 (0.24-1.02) 0.058   
More than 2 17.6 (32) 0.88 (0.40-1.96) 0.758   
Experience of CaCx      
No 61.5 (112) 1.00    
Yes 18.7 (34) 0.83 (0.39-1.80) 0.644   
Missing 19.8 (36)     
Heard of Pap test      
No 51.1 (93) 1.00  1.00  
Yes 29.1 (53) 2.00 (1.01-3.98) 0.047 1.73 (0.81-3.69) 0.158 
Missing 19.8 (36)     
Heard of HPV      
No 93.4 (170) 1.00    
Yes 6.6 (12) 0.87 (0.26-2.83) 0.810   
Heard of HPV vaccine      
No 85.2 (155) 1.00    
Yes 14.8 (27) 0.97 (0.43-2.22) 0.950   
Vaccine decision maker      
Father No 68.1 (124) 1.00    
 Yes 30.2 (55) 1.01 (0.54-1.92) 0.971   
Mother No 92.3 (168) 1.00    
 Yes   6.0 (11) 1.01 (0.30-3.43) 0.989   
Both No 39.6 (72) 1.00    
 Yes 58.8 (107) 1.06 (0.58-1.93) 0.859   
Doctor No 92.9 (169) 1.00    
 Yes   5.5 (10) 1.22 (0.34-4.38) 0.757   
Herself No 84.6 (154) 1.00    
 Yes 13.7 (25) 0.78 (0.33-1.84) 0.570   
Strongest reason to encourage 
acceptance 
     
Recommended by Ministry of 
Health/Doctor 
67.0 (122) 1.00  1.00  
Vaccine free 18.1 (33) 0.26 (0.11-0.63) 0.003 0.36 (0.12-1.06) 0.063 
Family member vaccinated their 
daughter 
  5.5 (10) 0.82 (0.23-2.98) 0.764 0.59 (0.13-2.75) 0.503 
Missing   1.1 (2)     
Continuous variables Range Mean (SD)     
Age 26-77 44.57 (9.45) 1.01 (0.98-1.04) 0.462   
Whatever happens to my health 
is God’s will 
  1-5   4.72 (0.65) 0.74 (0.44-1.27) 0.277   
Vaccine is expensive   1-5   3.71 (1.43) 0.59 (0.47-0.74) <0.001 0.74 (0.56-0.97) 0.037 
Insufficient information   1-5   4.80 (0.53) 1.19 (0.67-2.10) 0.557   
Encourages sexual liberty   1-5   2.23 (1.26) 0.83 (0.65-1.06) 0.135   
Vaccine doesn’t fully protect   1-5   3.06 (1.22) 0.76 (0.54-1.06) 0.101   
Concerns about post-vaccine 
complications 
  1-5   2.68 (1.49) 0.95 (0.77-1.16) 0.598   
Vaccine is new, want to wait   1-5   2.66 (1.56) 0.98 (0.81-1.19) 0.843   
an varies between items because of missing data 
bModel predicts 12.6-16.8% of the variance in vaccine acceptability (Cox & Snell R2=0.126, Nagelkerke R2=0.168) 
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